QView Medical

Executive Summary

QView Medical leverages artificial intelligence to enhance Automated Breast Ultrasound (ABUS) screening through its QVCAD system. As highlighted by a radiologist, QVCAD provides a comprehensive initial overview of ABUS exams, enabling faster and potentially more accurate detection of breast abnormalities. This technology is particularly valuable for women with dense breast tissue, where mammography alone may miss cancers. By integrating seamlessly into existing workflows, QVCAD addresses a critical gap in breast cancer screening, offering a higher perceived utility than traditional mammography CAD. Founded in 2015 and based in San Diego, QView Medical operates in the AI/ML diagnostics space and targets a large, underserved market. The company’s platform has the potential to reduce radiologist reading time and improve diagnostic consistency, positioning it for adoption in screening centers worldwide. Despite limited public financial data, the positive clinical feedback and growing emphasis on dense breast screening suggest strong market pull for QVCAD.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Expanded Indications70% success
• Q2 2026Publication of Large-Scale Clinical Validation Study60% success
• Q4 2026Strategic Partnership with Major Imaging OEM50% success